Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the recipient of unusually large options trading activity on Thursday. Traders acquired 869 put options on the stock. This represents an increase of Infinity compared to the typical daily volume of 0 put options.
In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 6,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $62.20, for a total transaction of $373,200.00. Following the transaction, the chief executive officer now directly owns 6,000 shares in the company, valued at approximately $373,200. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $61.99, for a total transaction of $133,030.54. Following the transaction, the insider now owns 8,410 shares in the company, valued at $521,335.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 178,908 shares of company stock worth $12,147,719. Corporate insiders own 10.55% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Spark Investment Management LLC lifted its stake in shares of Agios Pharmaceuticals by 139.9% in the 2nd quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock valued at $4,357,000 after purchasing an additional 49,400 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Agios Pharmaceuticals by 8.3% in the 1st quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock valued at $15,410,000 after purchasing an additional 20,336 shares during the last quarter. Hood River Capital Management LLC lifted its stake in shares of Agios Pharmaceuticals by 2.3% in the 2nd quarter. Hood River Capital Management LLC now owns 118,844 shares of the biopharmaceutical company’s stock valued at $6,115,000 after purchasing an additional 2,626 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth $743,000. Finally, Goldman Sachs Group Inc. lifted its position in Agios Pharmaceuticals by 4.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 681,093 shares of the biopharmaceutical company’s stock worth $35,042,000 after acquiring an additional 31,969 shares during the last quarter. 93.51% of the stock is owned by institutional investors and hedge funds.
Shares of Agios Pharmaceuticals (AGIO) opened at $62.05 on Friday. Agios Pharmaceuticals has a 52 week low of $39.24 and a 52 week high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The business had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same quarter in the previous year, the business earned ($1.63) EPS. Agios Pharmaceuticals’s quarterly revenue was up 26.4% compared to the same quarter last year. research analysts forecast that Agios Pharmaceuticals will post -6.59 earnings per share for the current fiscal year.
AGIO has been the topic of several research analyst reports. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank of Canada initiated coverage on shares of Agios Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price target on the stock. J P Morgan Chase & Co restated a “buy” rating and set a $76.00 price target on shares of Agios Pharmaceuticals in a report on Monday, September 18th. SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 price target on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. Finally, Janney Montgomery Scott restated a “hold” rating on shares of Agios Pharmaceuticals in a report on Tuesday, August 1st. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $75.70.
TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/12/investors-purchase-high-volume-of-agios-pharmaceuticals-put-options-agio.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.